Drug Profile
Cancer vaccine - Replikun Biotech
Alternative Names: KUN-GMCSF; KUNrep cancer vaccine - Replikun BiotechLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Replikun Biotech
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Oct 2010 Discontinued - Preclinical for Cancer in Australia (Parenteral)
- 28 Feb 2006 Replikun Biotech has been awarded $Aus1 million grant from AusIndustry to support development of KUN-GMCSF™ over the next 3 years
- 07 Feb 2006 KUN-GMCSF™ is available for licensing worldwide (http://www.replikun.com)